Market Cap | 3.01B | P/E | 32.29 | EPS this Y | - | Ern Qtrly Grth | 41.20% |
Income | 1.43B | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -1.00% |
Sales | 18.22B | PEG | - | EPS past 5Y | - | 200D Avg Chg | 9.00% |
Dividend | N/A | Price/Book | 3.77 | EPS next 5Y | - | 52W High Chg | -10.00% |
Recommedations | - | Quick Ratio | 0.82 | Shares Outstanding | 382.08M | 52W Low Chg | 66.00% |
Insider Own | - | ROA | 5.12% | Shares Float | 358.72M | Beta | 1.03 |
Inst Own | 0.01% | ROE | 14.44% | Shares Shorted/Prior | -/- | Price | 7.75 |
Gross Margin | 37.89% | Profit Margin | 7.87% | Avg. Volume | 3,787 | Target Price | - |
Oper. Margin | 13.42% | Earnings Date | Jun 5 | Volume | 636 | Change | -2.78% |
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.